Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Michelle N. Rheault is active.

Publication


Featured researches published by Michelle N. Rheault.


Cell | 2007

Distinct target-derived signals organize formation, maturation, and maintenance of motor nerve terminals

Michael A. Fox; Joshua R. Sanes; Dorin-Bogdan Borza; Veraragavan P. Eswarakumar; Reinhard Fässler; Billy G. Hudson; Simon W. M. John; Yoshifumi Ninomiya; Vadim Pedchenko; Samuel L. Pfaff; Michelle N. Rheault; Yoshikazu Sado; Yoav Segal; Michael J. Werle; Hisashi Umemori

Target-derived factors organize synaptogenesis by promoting differentiation of nerve terminals at synaptic sites. Several candidate organizing molecules have been identified based on their bioactivities in vitro, but little is known about their roles in vivo. Here, we show that three sets of organizers act sequentially to pattern motor nerve terminals: FGFs, beta2 laminins, and collagen alpha(IV) chains. FGFs of the 7/10/22 subfamily and broadly distributed collagen IV chains (alpha1/2) promote clustering of synaptic vesicles as nerve terminals form. beta2 laminins concentrated at synaptic sites are dispensable for embryonic development of nerve terminals but are required for their postnatal maturation. Synapse-specific collagen IV chains (alpha3-6) accumulate only after synapses are mature and are required for synaptic maintenance. Thus, multiple target-derived signals permit discrete control of the formation, maturation, and maintenance of presynaptic specializations.


Journal of The American Society of Nephrology | 2004

Mouse Model of X-Linked Alport Syndrome

Michelle N. Rheault; Stefan M. Kren; Beth K. Thielen; Hector Mesa; John T. Crosson; William Thomas; Yoshikazu Sado; Clifford E. Kashtan; Yoav Segal

X-linked Alport syndrome (XLAS) is a progressive disorder of basement membranes caused by mutations in the COL4A5 gene, encoding the alpha5 chain of type IV collagen. A mouse model of this disorder was generated by targeting a human nonsense mutation, G5X, to the mouse Col4a5 gene. As predicted for a nonsense mutation, hemizygous mutant male mice are null and heterozygous carrier female mice are mosaic for alpha5(IV) chain expression. Mutant male mice and carrier female mice are viable through reproductive age and fertile. Mutant male mice died spontaneously at 6 to 34 wk of age, and carrier female mice died at 8 to 45 wk of age, manifesting proteinuria, azotemia, and progressive and manifold histologic abnormalities of the kidney glomerulus and tubulointerstitium. Ultrastructural abnormalities of the glomerular basement membrane, including lamellation and splitting, were characteristic of human XLAS. The mouse model described here recapitulates essential clinical and pathologic findings of human XLAS. With alpha5(IV) expression reflecting X-inactivation patterns, it will be especially useful in studying determinants of disease variability in the carrier state.


Pediatric Nephrology | 2013

Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative

Clifford E. Kashtan; Jie Ding; Martin C. Gregory; Oliver Gross; Laurence Heidet; Bertrand Knebelmann; Michelle N. Rheault; Christoph Licht

We present clinical practice recommendations for the treatment of children with Alport syndrome who are not enrolled in clinical trials. Our goal is to promote early initiation of a standard therapeutic approach that will facilitate assessment of the safety and efficacy of the protocol. The treatment protocol is based on the reduction of proteinuria, intraglomerular pressure, and renal fibrosis via interference with the renin–angiotensin–aldosterone system.


Journal of The American Society of Nephrology | 2015

HLA-DQA1 and PLCG2 Are Candidate Risk Loci for Childhood-Onset Steroid-Sensitive Nephrotic Syndrome

Rasheed Gbadegesin; Adebowale Adeyemo; Nicholas J. A. Webb; Larry A. Greenbaum; Asiri Abeyagunawardena; Shenal Thalgahagoda; Arundhati S. Kale; Debbie S. Gipson; Tarak Srivastava; Jen Jar Lin; Deepa H. Chand; Tracy E. Hunley; Patrick D. Brophy; Arvind Bagga; Aditi Sinha; Michelle N. Rheault; Joanna Ghali; Kathy Nicholls; Elizabeth Abraham; Halima S. Janjua; Abiodun Omoloja; Gina Marie Barletta; Yi Cai; David D. Milford; Catherine O'Brien; Atif Awan; Vladimir Belostotsky; William E. Smoyer; Alison Homstad; Gentzon Hall

Steroid-sensitive nephrotic syndrome (SSNS) accounts for >80% of cases of nephrotic syndrome in childhood. However, the etiology and pathogenesis of SSNS remain obscure. Hypothesizing that coding variation may underlie SSNS risk, we conducted an exome array association study of SSNS. We enrolled a discovery set of 363 persons (214 South Asian children with SSNS and 149 controls) and genotyped them using the Illumina HumanExome Beadchip. Four common single nucleotide polymorphisms (SNPs) in HLA-DQA1 and HLA-DQB1 (rs1129740, rs9273349, rs1071630, and rs1140343) were significantly associated with SSNS at or near the Bonferroni-adjusted P value for the number of single variants that were tested (odds ratio, 2.11; 95% confidence interval, 1.56 to 2.86; P=1.68×10(-6) (Fisher exact test). Two of these SNPs-the missense variants C34Y (rs1129740) and F41S (rs1071630) in HLA-DQA1-were replicated in an independent cohort of children of white European ancestry with SSNS (100 cases and ≤589 controls; P=1.42×10(-17)). In the rare variant gene set-based analysis, the best signal was found in PLCG2 (P=7.825×10(-5)). In conclusion, this exome array study identified HLA-DQA1 and PLCG2 missense coding variants as candidate loci for SSNS. The finding of a MHC class II locus underlying SSNS risk suggests a major role for immune response in the pathogenesis of SSNS.


Pediatric Blood & Cancer | 2011

Reversible Fanconi syndrome in a pediatric patient on deferasirox

Michelle N. Rheault; Heather Bechtel; Joseph P. Neglia; Clifford E. Kashtan

Deferasirox (Exjade®, Novartis) is a widely used oral iron chelator for the treatment of patients with iron overload due to chronic transfusion therapy for diseases such as β‐thalassemia and sickle cell disease. Renal side effects of deferasirox are common and include non‐progressive increases in serum creatinine, however, the effect of deferasirox on proximal tubule function is unclear. We report one pediatric patient with reversible Fanconi syndrome associated with long‐term deferasirox therapy and one patient with mild proximal tubular dysfunction. Kidney and proximal tubular function should be periodically monitored in patients receiving deferasirox throughout their course of therapy. Pediatr Blood Cancer 2011;56:674–676.


Pediatric Nephrology | 2012

Women and Alport syndrome

Michelle N. Rheault

X-linked Alport syndrome (XLAS) is caused by mutations in type IV collagen causing sensorineural hearing loss, eye abnormalities, and progressive kidney dysfunction that results in near universal end-stage renal disease (ESRD) and the need for kidney transplantation in affected males. Until recent decades, the disease burden in heterozygous “carrier” females was largely minimized or ignored. Heterozygous females have widely variable disease outcomes, with some affected females exhibiting normal urinalysis and kidney function, while others develop ESRD and deafness. While the determinants of disease severity in females with XLAS are uncertain, skewing of X-chromosome inactivation has recently been found to play a role. This review will explore the natural history of heterozygous XLAS females, the determinants of disease severity, and the utility of using XLAS females as kidney donors.


Clinical Journal of The American Society of Nephrology | 2011

Kidney Function Reference Values in US Adolescents: National Health and Nutrition Examination Survey 1999–2008

Blanche M. Chavers; Michelle N. Rheault; Robert N. Foley

BACKGROUND AND OBJECTIVES Few data are available on kidney function in normal US adolescents. This study characterizes the distribution of kidney function measures and associated factors. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS Serum creatinine, cystatin C, and urinary albumin-to-creatinine ratios were measured in US adolescents (aged 12 to 17 years; n = 5575) in the cross-sectional National Health and Nutrition Examination Survey 1999-2008. The reference population was defined as healthy adolescents with BP <120/80 mmHg and a Z-score for weight-to-height ≤1.645, without self-reported diabetes or hypertension, not using prescription medications in the preceding 30 days, not pregnant or currently menstruating. RESULTS were analyzed by age, gender, race, ethnicity, body mass index, and BP; estimated GFR (eGFR) was calculated using the original and revised Schwartz formulas. Results Mean values for eGFR(Schwartz original formula), serum creatinine, and serum cystatin C were 147 ml/min/1.73 m(2), 0.71 mg/dl, 0.82 mg/L, respectively. The median urinary albumin-to-creatinine ratio was 6.8 mg/g creatinine. In the reference population (n = 2881), eGFR differed significantly using the two Schwartz formulas; values were higher using the original formula (median values 143 versus 96 ml/min/1.73 m(2)). Serum creatinine level (0.7 versus 0.72 mg/dl), but not cystatin C level (0.82 versus 0.82 mg/L), was lower in the reference population than in a nonreference population of adolescents. CONCLUSIONS These findings provide important demographic information and highlight the need for confirmatory testing of the revised Schwartz formula by comparison to measured GFR in healthy US adolescents.


Nephrology Dialysis Transplantation | 2010

X-inactivation modifies disease severity in female carriers of murine X-linked Alport syndrome

Michelle N. Rheault; Stefan M. Kren; Linda A. Hartich; Melanie M. Wall; William Thomas; Hector Mesa; Philip Avner; George E. Lees; Clifford E. Kashtan; Yoav Segal

BACKGROUND Female carriers of X-linked Alport syndrome (XLAS) demonstrate variability in clinical phenotype that, unlike males, cannot be correlated with genotype. X-inactivation, the method by which females (XX) silence transcription from one X chromosome in order to achieve gene dosage parity with males (XY), likely modifies the carrier phenotype, but this hypothesis has not been tested directly. METHODS Using a genetically defined mouse model of XLAS, we generated two groups of Alport female (Col4a5(+/-)) carriers that differed only in the X-controlling element (Xce) allele regulating X-inactivation. We followed the groups as far as 6 months of age comparing survival and surrogate outcome measures of urine protein and plasma urea nitrogen. RESULTS Preferential inactivation of the mutant Col4a5 gene improved survival and surrogate outcome measures of urine protein and plasma urea nitrogen. In studies of surviving mice, we found that X-inactivation in kidney, measured by allele-specific mRNA expression assays, correlated with surrogate outcomes. CONCLUSIONS Our findings establish X-inactivation as a major modifier of the carrier phenotype in X-linked Alport syndrome. Thus, X-inactivation patterns may offer prognostic information and point to possible treatment strategies for symptomatic carriers.


Clinical Journal of The American Society of Nephrology | 2015

AKI in Children Hospitalized with Nephrotic Syndrome

Michelle N. Rheault; Lei Zhang; David T. Selewski; Mahmoud Kallash; Cheryl L. Tran; Meredith Seamon; Chryso Katsoufis; Isa F. Ashoor; Joel D. Hernandez; Katarina Supe-Markovina; Cynthia D'Alessandri-Silva; Nilka DeJesus-Gonzalez; Tetyana L. Vasylyeva; Cassandra Formeck; Christopher Woll; Rasheed Gbadegesin; Pavel Geier; Prasad Devarajan; Shannon L. Carpenter; Bryce A. Kerlin; William E. Smoyer

BACKGROUND AND OBJECTIVES Children with nephrotic syndrome can develop life-threatening complications, including infection and thrombosis. While AKI is associated with adverse outcomes in hospitalized children, little is known about the epidemiology of AKI in children with nephrotic syndrome. The main objectives of this study were to determine the incidence, epidemiology, and hospital outcomes associated with AKI in a modern cohort of children hospitalized with nephrotic syndrome. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS Records of children with nephrotic syndrome admitted to 17 pediatric nephrology centers across North America from 2010 to 2012 were reviewed. AKI was classified using the pediatric RIFLE definition. RESULTS AKI occurred in 58.6% of 336 children and 50.9% of 615 hospitalizations (27.3% in stage R, 17.2% in stage I, and 6.3% in stage F). After adjustment for race, sex, age at admission, and clinical diagnosis, infection (odds ratio, 2.24; 95% confidence interval, 1.37 to 3.65; P=0.001), nephrotoxic medication exposure (odds ratio, 1.35; 95% confidence interval, 1.11 to 1.64; P=0.002), days of nephrotoxic medication exposure (odds ratio, 1.10; 95% confidence interval, 1.05 to 1.15; P<0.001), and intensity of medication exposure (odds ratio, 1.34; 95% confidence interval, 1.09 to 1.65; P=0.01) remained significantly associated with AKI in children with nephrotic syndrome. Nephrotoxic medication exposure was common in this population, and each additional nephrotoxic medication received during a hospitalization was associated with 38% higher risk of AKI. AKI was associated with longer hospital stay after adjustment for race, sex, age at admission, clinical diagnosis, and infection (difference, 0.45 [log]days; 95% confidence interval, 0.36 to 0.53 [log]days; P<0.001). CONCLUSIONS AKI is common in children hospitalized with nephrotic syndrome and should be deemed the third major complication of nephrotic syndrome in children in addition to infection and venous thromboembolism. Risk factors for AKI include steroid-resistant nephrotic syndrome, infection, and nephrotoxic medication exposure. Children with AKI have longer hospital lengths of stay and increased need for intensive care unit admission.


American Journal of Kidney Diseases | 2017

The Evolution of the Journal Club: From Osler to Twitter

Joel Topf; Matthew A. Sparks; Paul J. Phelan; Nikhil Shah; Edgar V. Lerma; Matthew P.M. Graham-Brown; Hector Madariaga; Francesco Iannuzzella; Michelle N. Rheault; Thomas Oates; Kenar D. Jhaveri; Swapnil Hiremath

Journal clubs have typically been held within the walls of academic institutions and in medicine have served the dual purpose of fostering critical appraisal of literature and disseminating new findings. In the last decade and especially the last few years, online and virtual journal clubs have been started and are flourishing, especially those harnessing the advantages of social media tools and customs. This article reviews the history and recent innovations of journal clubs. In addition, the authors describe their experience developing and implementing NephJC, an online nephrology journal club conducted on Twitter.

Collaboration


Dive into the Michelle N. Rheault's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Oliver Gross

University of Göttingen

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge